Resistance to Chemotherapy in Breast Cancer
Author:
Publisher
Springer Nature Switzerland
Link
https://link.springer.com/content/pdf/10.1007/978-3-031-52860-6_6
Reference146 articles.
1. Achinger-Kawecka, J., Valdes-Mora, F., Luu, P.-L., Giles, K. A., Caldon, C. E., Qu, W., et al. (2020). Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine-resistant breast cancer. Nature Communications, 11, 320.
2. Adams, S., Loi, S., Toppmeyer, D., Cescon, D., De Laurentiis, M., Nanda, R., et al. (2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology, 30, 405–411.
3. Ahmed, K., Koval, A., Xu, J., Bodmer, A., & Katanaev, V. L. (2019). Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor. Cancer Letters, 449, 45–55.
4. Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., et al. (2015). Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell International, 15, 1–13.
5. Allahverdiyev, A. M., Parlar, E., Dinparvar, S., Bagirova, M., & Abamor, E. Ş. (2018). Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects. Artificial Cells, Nanomedicine, and Biotechnology, 46, 755–762.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3